SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Posterior Segment Delivery Drugs Systems

Arka Segment İlaç Salınım Sistemleri

Özgür YALÇINBAYIR
Pages
63–68
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the future, new horizons emerge in the treatment of posterior segment diseases with the developments in ophthalmic pharma- cology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite the significant improvements in the treatment of poste- rior segment diseases in recent years, there are still pharmacod- ynamic problems with those drugs due to the physiological and anatomic constraints within the eye.
📊
Key Findings & Data:Although intra- vitreal implants help to increase the duration and dosage of the molecule, they have an increased side eff ect profile with repeated applications.
💡
Conclusion & Impact:In the future, new horizons emerge in the treatment of posterior segment diseases with the developments in ophthalmic pharma- cology.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite the significant improvements in the treatment of poste- rior segment diseases in recent years, there are still pharmacod- ynamic problems with those drugs due to the physiological and anatomic constraints within the eye. At present, the treatment of posterior segment disease is usually applied with local drug administrations, mainly by intravitreal route. Although intra- vitreal implants help to increase the duration and dosage of the molecule, they have an increased side eff ect profile with repeated applications. Systems that allow delivery of the drugs to the suprachoroidal space are promising because of the prolonged release to the pos- terior segment. It is also anticipated that encapsulated cell tech- nology, port-release systems and drug coating technologies will have an impact on increasing the treatment eff icacy of retinal diseases by allowing a longer intravitreal drug stay. In the future, new horizons emerge in the treatment of posterior segment diseases with the developments in ophthalmic pharma- cology.

Özet

Son yıllarda arka segment hastalıklarının tedavisinde önemli gelişmeler yaşanmasına rağmen, gözdeki fizyolojik ve anatomik kısıtlamalar ilaçların istenilen süre ve dozda etki sağlamasını engellemektedir. Günümüzde arka segment hastalıklarının te- davisi genellikle intravitreal yol başta olmak üzere lokal ilaç uy- gulamaları şeklinde yapılmaktadır. İntravitreal implantlar, etki süresini ve dozunu arttırsa da tekrarlanan uygulamalar ile ciddi yan etki profili gelişmektedir. Suprakoroidal alana ilaçların verilmesini sağlayan sistemler, arka segmentte uzamış salınım sağlaması nedeniyle ümit vaat etmektedir. Yine intravitreal alanda ilacın daha uzun süre kal- masını sağlayabilecek enkapsüle hücre teknolojisi, port salınım sistemleri ve ilaç kaplama teknolojilerinin retinal hastalıklardaki etkinliğin arttırılması konusunda etkisi olması beklenmektedir. Oftalmik farmakolojide yaşanan gelişmeler ile arka segment has- talıklarının tedavisinde yeni ufuklar görünmektedir.

🔖

Cite This Article

YALÇINBAYIR, Ö. (2017). Posterior Segment Delivery Drugs Systems. Retina-Vitreus, Cilt: 26 - Sayı: 0, 63–68. https://ajindex.com/articles/304921

References (14)

  1. Bansal P, Garg S, Sharma Y et al. Venkatesh P. Posterior Seg- ment Drug Delivery Devices: Current and Novel Therapies in Development. J Ocul Pharmacol Ther. 2016;32:135-44.
  2. Fangueiro JF, Veiga F, Silva AM et al. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye. Curr Pharm Des. 2016;22:1135-46.
  3. Chang-Lin JE, Attar M, Acheampong AA et al. Pharmacokineti- cs and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-6.
  4. Boyer DS, Yoon YH, Belfort R Jr et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904-14.
  5. Hughes PM, Olejnik O, Chang-Lin JE et al. Topical and syste- mic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005;57:2010–2032. Urtti A: Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131–1315.
  6. Kuppermann BD, Loewenstein A. Drug Delivery to the Posterior Segment of the Eye. Dev Ophthalmol.2010;47, 59–72
  7. Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone aceto- nide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther. 2013; 7: 425–434.
  8. Pearson PA, Comstock TL, Ip M et al. Fluocinolone acetonide int- ravitreal implant for diabetic macular edema: a 3-year multicen- ter, randomized, controlled clinical trial. Ophthalmology. 2011; 118:1580-7
  9. Campochiaro PA, Brown DM, Pearson A et al. Sustained delivery fl uocinolone acetonide vitreous inserts provide benefit for at le- ast 3 years in patients with diabetic macular edema. Ophthalmo- logy 2012;119:2125-2132.
  10. Edelhauser HF, Rowe-Rendleman CL, Robinson MR et al. Oph- thalmic drug delivery systems for the treatment of retinal dise- ases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010; 1:5403-5420.
  11. Olsen TW, Feng X, Wabner K, Conston SR et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142:777-787.
  12. Rizzo S, Ebert FG, Bartolo ED et al. Suprachoroidal drug infusi- on for the treatment of severe subfoveal hard exudates. Retina. 2012;32:776-784.
  13. Tetz M, Rizzo S, Augustin AJ. Safety of submacular supracho- roidal drug administration via a microcatheter: retrospecti- ve analysis of European treatment results. Ophthalmologica. 2012;227:183-189.
  14. Patel SR, Lin AS, Edelhauser HF et al. Suprachoroidal drug